NASDAQ · Analyst Forecast

Relay Therapeutics, Inc. (RLAY) Stock Forecast & Price Target

$16.47 NASDAQ: RLAY Market Cap $3.64B

Price as of Nov 17, 2026 close · Analyst estimates retrieved Nov 12, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)

Revenue and earnings estimates published by analysts covering Relay Therapeutics, Inc. (RLAY), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.

For Relay Therapeutics, Inc., analysts forecast revenue rising from $12.81M in 2025 to $463.44M in 2030; the average estimate for 2030 earnings per share is −$0.28; with published estimates ranging from −$1.01 to −$0.11; 9 analysts contribute to these figures. These are forecasts published by analysts, not results.

Analyst price targets

MeasureValue
Current priceWhat the share trades at now.$16.47
Consensus targetThe average of the price targets analysts have published.$28.50
Median targetThe middle target, less affected by a single outlier.$29.00
Highest targetThe most optimistic published target.$31.00
Lowest targetThe most pessimistic published target.$26.00
Difference from priceHow far the consensus target sits from today’s price.+73.0%

A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.

Revenue forecast (USD)

The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.

YearLowAverageHighAnalysts
2025$5.49M$12.81M$25.20M7
2026$7.73M$9.82M$12.34M9
2027$7.89M$11.55M$15.20M9
2028$11.22M$20.32M$61.97M9
2029$98.67M$178.62M$544.85M4
2030$255.99M$463.44M$1.41B4

Earnings per share forecast

YearLowAverageHighAnalysts
2025−$1.79−$1.73−$1.557
2026−$1.67−$1.55−$1.499
2027−$1.64−$1.58−$1.539
2028−$1.85−$1.58−$1.449
2029−$4.00−$1.09−$0.464
2030−$1.01−$0.28−$0.114

Relay Therapeutics, Inc. (RLAY) forecast — frequently asked questions

What is the analyst price target for Relay Therapeutics, Inc.?

Analysts covering Relay Therapeutics, Inc. (RLAY) have a consensus price target of $28.50, 73.0% above the current price of $16.47. Published targets range from $26.00 to $31.00. A price target is a forecast, not a measure of value, and targets are revised often.

What are analysts forecasting for Relay Therapeutics, Inc.'s earnings?

The average analyst estimate for Relay Therapeutics, Inc. (RLAY) earnings per share in 2030 is -0.28, with individual estimates between -1.01 and -0.11.

How much revenue is Relay Therapeutics, Inc. expected to make?

Analysts forecast Relay Therapeutics, Inc. (RLAY) revenue of $463.44M in 2030, based on 4 published estimates.

How many analysts cover RLAY?

9 analysts contribute estimates for Relay Therapeutics, Inc. (RLAY). Thin coverage makes an average less reliable.

Analyst forecasts for other Biotechnology stocks

VRTX forecastREGN forecastMRNA forecastRVMD forecastROIV forecastINSM forecastUTHR forecastINCY forecastALNY forecastASND forecastAll Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.